{
    "Trade/Device Name(s)": [
        "BD ProbeTecTM ET Chlamydia trachomatis and Neisseria gonorrhoeae Amplified DNA Assays",
        "BD ProbeTecTM Urine Preservative Transport (UPT)"
    ],
    "Submitter Information": "Becton, Dickinson and Company",
    "510(k) Number": "K052224",
    "Predicate Device Reference 510(k) Number(s)": [
        "K984631"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LSL",
        "MKZ"
    ],
    "Summary Letter Date": "September 12, 2005",
    "Summary Letter Received Date": "August 16, 2005",
    "Submission Date": "August 15, 2005",
    "Regulation Number(s)": [
        "21 CFR 866.3390"
    ],
    "Regulation Name(s)": [
        "Neisseria spp. direct serological test reagents"
    ],
    "Analyte Class(es)": [
        "microbiology",
        "virology"
    ],
    "Analyte(s)": [
        "Chlamydia trachomatis DNA",
        "Neisseria gonorrhoeae DNA"
    ],
    "Specimen Type(s)": [
        "Endocervical swab",
        "Male urethral swab",
        "Female urine",
        "Male urine"
    ],
    "Specimen Container(s)": [
        "BD ProbeTecTM Urine Preservative Transport (UPT)",
        "Neat urine container"
    ],
    "Instrument(s)/Platform(s)": [
        "BD ProbeTec ET System",
        "BD Viper instrument"
    ],
    "Method(s)/Technology(ies)": [
        "Strand Displacement Amplification (SDA)",
        "Fluorescent energy transfer (ET) detection"
    ],
    "Methodologies": [
        "Qualitative DNA amplification and detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Specimen collection device",
        "Transport medium"
    ],
    "Document Summary": "FDA 510(k) summary for BD ProbeTec ET CT/GC Amplified DNA Assays and BD ProbeTec Urine Preservative Transport for direct qualitative detection of Chlamydia trachomatis and Neisseria gonorrhoeae DNA.",
    "Indications for Use Summary": "Direct, qualitative detection of Chlamydia trachomatis and Neisseria gonorrhoeae DNA in endocervical swabs, male urethral swabs, and male and female urine specimens using Strand Displacement Amplification technology, for evidence of infection or coinfection in symptomatic and asymptomatic individuals.",
    "fda_folder": "Microbiology"
}